PIRAMAL CRITICAL CARE LIMITED

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -4.3%

  £25,812,254 → £24,695,063

• Cash

  +173.6%

  £2,087,147 → £5,709,827

• Net assets

  -35.9%

  -£32,806,214 → -£44,597,625

• Employees

  -12.1%

  33 → 29

• Operating profit

  +49%

  -£7,013,200 → -£3,573,309

• Profit before tax

  +28.9%

  -£16,584,739 → -£11,791,411

• Wages

  -23%

  £3,780,853 → £2,911,761

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. PIRAMAL CRITICAL CARE LIMITED 2015-12-17 → present
2. PIRAMAL LIFE SCIENCES (UK) LIMITED 2010-03-12 → 2015-12-17
3. NPIL LIFE SCIENCES LTD 2004-06-22 → 2010-03-12

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

KNAV Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have made an assessment and confirm that the Company will have sufficient funds, either through its operations, financing facilities available to it or funding from its ultimate parent company, Piramal Pharma Limited, to meet its liabilities as they fall due for that period. Piramal Pharma Limited has indicated its intention to continue to make available such funds to meet its liabilities as they fall due for the period of at least 12 months from the approval of the financial statements. Therefore, the directors have prepared the financial statements on a going concern basis.”

Group structure

1. PIRAMAL CRITICAL CARE LIMITED · parent
   1. Piramal Critical Care South Africa (PTY) Limited 100% · South Africa
   2. Piramal Critical Care Pty Ltd 100% · Australia

Significant events

• “supply challenges experienced by certain contract manufacturing partners impacted product availability; however, the Company has proactively identified and progressed alternate CMO arrangements to stabilise and strengthen supply continuity going forward.”
• “successful renewal of the national Sevoflurane tender for an additional two year period, alongside winning the Sevoflurane tender in Wales.”
• “soft launched a new product, with a strategic focus on a broader commercial launch in 2026.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.